Skip to main content
SpringerLink
Log in

Innovationen für morgen und übermorgen

Medikamentöse Herzinsuffizienztherapie

  • Zertifizierte Fortbildung
  • Published:
CardioVasc Aims and scope

Zusammenfassung

Die chronische Herzinsuffizienz ist eine der häufigsten chronischen Erkrankungen weltweit mit steigender Prävalenz und Inzidenz. Eine optimale medikamentöse Therapie ist bei hoher Morbidität und Mortalität essenziell. Die nachfolgende Übersicht erläutert neue innovative Therapieoptionen in der Behandlung der Herzinsuffizienz, aufbauend auf den aktuellen Leitlinien der Europäischen Gesellschaft für Kardiologie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2016;37(27):2129–200

    Article  PubMed  Google Scholar 

  2. Tsao CW, Lyass A, Larson MG et al. Prognosis of adults with borderline left ventricular ejection fraction. J Am Coll HF. 2016;4:502–10

    Google Scholar 

  3. Faris RF, Flather M, Purcell H et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012;2:DC003838.

    Google Scholar 

  4. Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. 2002;82:149–58

    Article  CAS  PubMed  Google Scholar 

  5. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Circulation. 2005;112:2426–35

    Article  CAS  PubMed  Google Scholar 

  6. Albert NM, Yancy CW, Liang L et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658–65

    Article  CAS  PubMed  Google Scholar 

  7. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med. 2004;351:585–92

    Article  CAS  PubMed  Google Scholar 

  8. Weir MR, Bakris LG, Bushinsky DA et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211–21

    Article  PubMed  Google Scholar 

  9. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004

    Article  PubMed  Google Scholar 

  10. Jhund PS, Fu M, Bayram E et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576–84

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kristensen SL, Preiss D, Jhund PS et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016 Jan;9(1), doi:10.1161/CIRCHEARTFAILURE.115.002560

    Google Scholar 

  12. Simpson J, Jhund PS, Cardoso JS et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores. J Am Coll Cardiol. 2015;66:2059–71

    Article  CAS  PubMed  Google Scholar 

  13. Packer M, McMurray JJ, Desai AS et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61

    Article  CAS  PubMed  Google Scholar 

  14. Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebocontrolled trial. Lancet. 2010;376:886–94

    Article  PubMed  Google Scholar 

  15. Reil JC, Böhm M. BEAUTIFUL results-the slower, the better? Lancet. 2008;372(9641):779–80

    Article  PubMed  Google Scholar 

  16. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010;376:875–85

    Article  CAS  PubMed  Google Scholar 

  17. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care 2004;27:699–703

    Article  PubMed  Google Scholar 

  18. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. 2015;373(22): 2117–28

    CAS  Google Scholar 

  19. Fitchett D, Zinman B, Wanner C et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526–34

    Article  PubMed  PubMed Central  Google Scholar 

  20. Zile MR, Bennett TD, St. John Sutton M et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Ciruclation. 2008;118:1433–41

    Article  Google Scholar 

  21. Adamson PB, Abraham WT, Aaron M et al. CHAMPION trial rationale and design: the longterm safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail. 2011;17:3–10

    Article  PubMed  Google Scholar 

  22. Abraham WT, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377:658–66

    Article  PubMed  Google Scholar 

  23. Costanzo MR, Stevenson LW, Adamson PB et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. J Am Coll Cardiol HF. 2016;4:333–4

    Google Scholar 

Literatur

  1. www.springermedizin.de/cardiovasc

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstraße 100, 66424, Homburg/Saar, Deutschland

    Yvonne Bewarder,  Sebastian Ewen,  Ingrid Kindermann &  Michael Böhm

Authors
  1. Yvonne Bewarder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Ewen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingrid Kindermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvonne Bewarder.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bewarder, Y., Ewen, S., Kindermann, I. et al. Medikamentöse Herzinsuffizienztherapie. CV 17, 31–37 (2017). https://doi.org/10.1007/s15027-017-1052-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-017-1052-x

Search

Navigation